Apple Turns 50: From Garage Startup to AI Crossroads 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
PARIS and NEW YORK, Sept. 22, 2016 -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will host a conference call on Thursday, September 29, 2016 at 12:00 p.m. Eastern Time (6:00 p.m. Central European Time) to discuss top-line results from the recently completed Phase IIa clinical trial of lead drug candidate QGC001, in hypertension.
Additional details on access to conference call are as follows:
| Date: | Thursday, September 29th, 2016 |
| Time: | 12:00 PM ET/ 6:00 PM CET |
| Dial-in numbers: | 1-888-740-6143 (U.S.) / 1-913-312-1427 (International) |
| Passcode: | 6527238 |
| Replay dial-in numbers: | 1-844-512-2921 (U.S.) / 1-412-317-6671 (International) |
A brief slide presentation will accompany the call. It will be available prior to the call on the "Investor Presentations" page of the "Investor" section on the Company’s website.
| Presentation Link: | http://www.quantum-genomics.com/www/en/investors/investors presentations/ | |
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
CONTACTS Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 [email protected] ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 [email protected] The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592
